Prosecution Insights
Last updated: April 19, 2026
Application No. 18/003,088

KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE

Non-Final OA §102
Filed
Dec 22, 2022
Examiner
SANCHEZ, JUSTIN CHRISTOPHER
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Icahn School Of Medicine AT Mount Sinai
OA Round
1 (Non-Final)
84%
Grant Probability
Favorable
1-2
OA Rounds
3y 5m
To Grant
94%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allow Rate
27 granted / 32 resolved
+24.4% vs TC avg
Moderate +10% lift
Without
With
+10.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
27 currently pending
Career history
59
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
29.0%
-11.0% vs TC avg
§102
19.1%
-20.9% vs TC avg
§112
31.6%
-8.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 32 resolved cases

Office Action

§102
DETAILED ACTION Claims 1-2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 35, 51, 55, and 65, submitted 18 September 2025, are pending in the application. Claims 1-2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 51 are under examination in the instant Office Action. Claims 30, 35, 55, and 65 are withdrawn. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, claims 1-2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 51, and the elected species of compound, PNG media_image1.png 74 158 media_image1.png Greyscale , in the reply filed on 15 December 2025 is acknowledged. Claims 30, 35, 55, and 65 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Group, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 15 December 2025. The Examiner did not find prior art on the elected species. In the search of the claimed species, prior art which reads on the genus and subsequent compounds of the claimed invention was found. Thus, the species election was expanded to include species identified in the below prior art rejection. As detailed in the following art rejection, the generic claim encompassing the elected species was not found patentable. Specification The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 51 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Takahashi et al. (USPN 9,783,522). Takahashi discloses a genus, shown below, similar to that of the Applicant. Takahashi also exemplifies a compound, shown below, which reads on the limitations of the instantly claimed genus, also shown below. This reference teaches a compound which reads on the limitations of the genus when Z1, Z2, and Z3 = carbon; R1 = -OCF3; R2 and R3 both = hydrogen; Z4 = carbon; R4 = hydrogen (Col 4, Lines 15-29); A = a heteroaryl, PNG media_image2.png 88 162 media_image2.png Greyscale (Col. 13, Line 55); L1 = -X2-, wherein X2 = single bond; and R5 and R6 = -X1-R7a, wherein X1 = single bond and R7a = hydrogen (Col. 4, Lines 30-47). Genus taught by Takahashi PNG media_image3.png 166 406 media_image3.png Greyscale (Col. 4, Lines 5-13) Compound taught by Takahashi PNG media_image4.png 162 400 media_image4.png Greyscale (Col 85, Example 8) Genus taught by Applicant PNG media_image5.png 105 260 media_image5.png Greyscale By comparison, instant claim 1 teaches an identical compound when R2 = -OCF3; Y = unbranched C1 alkyl; R1 = NH; Q = CH; L = a bond; and X = PNG media_image6.png 91 111 media_image6.png Greyscale , wherein R4 = COOH. Claims 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 51 are rejected as they are dependent claims stemming from the rejected independent claim 1. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JUSTIN CHRISTOPHER SANCHEZ whose telephone number is (703)756-5336. The examiner can normally be reached Monday -Friday (0730-1700). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. JUSTIN CHRISTOPHER SANCHEZ Examiner Art Unit 1622 /J.C.S./Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Dec 22, 2022
Application Filed
Jan 15, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594271
COMBINATION THERAPY FOR CANCER
2y 5m to grant Granted Apr 07, 2026
Patent 12558348
BIOACTIVE PHYTOCHEMICALS
2y 5m to grant Granted Feb 24, 2026
Patent 12551463
DOSING OF A BRUTON'S TYROSINE KINASE INHIBITOR
2y 5m to grant Granted Feb 17, 2026
Patent 12551471
ABT-751 AND IONIZING RADIATION
2y 5m to grant Granted Feb 17, 2026
Patent 12527753
Cysteamine for the Treatment, Mitigation and Prevention of Coronaviral, e.g., SARS-CoV-2, Infections
2y 5m to grant Granted Jan 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
84%
Grant Probability
94%
With Interview (+10.0%)
3y 5m
Median Time to Grant
Low
PTA Risk
Based on 32 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month